OBJECTIVE: To examine whether disease duration is an independent predictor of achieving remission in rheumatoid arthritis (RA) patients initiating therapy. METHODS: RA patients in the Consortium of Rheumatology Researchers of North America registry newly prescribed a nonbiologic disease-modifying antirheumatic drug (DMARD) or anti--tumor necrosis factor (anti-TNF) with at least one followup visit were identified. Achievement of remission was defined using the Clinical Disease Activity Index (CDAI; score ≤2.8) and 28-joint Disease Activity Score (DAS28; score <2.6) at any followup visit within one year; sustained remission was defined as remission during any two successive visits. Likelihood of remission was examined through logistic regression based on 5-year increments of disease duration, adjusting for baseline covariates. RESULTS: Among the 1,646 nonbiologic DMARD initiators, CDAI remission occurred in 21.3% of those with ≤5 years of disease duration, 19.6% with 6-10 years, and 13.5% with ≥11 years (P < 0.001); sustained remission occurred in 10.2%, 8.8%, and 2.5%, respectively (P < 0.001). Results were similar among the 3,179 anti-TNF initiators (CDAI remission in 22.3%, 17.7%, and 12.8%, respectively [P < 0.001]; CDAI sustained remission in 9.7%, 9.5%, and 4.2%, respectively [P < 0.001]). DAS28 results were similar in both groups. In adjusted analyses, an increase of disease duration by 5 years was associated with a reduced likelihood of CDAI remission in nonbiologic DMARD (odds ratio [OR] 0.91, 95% confidence interval [95% CI] 0.83-0.99) and anti-TNF initiators (OR 0.88, 95% CI 0.83-0.94). A similar result was seen for sustained remission using the CDAI (nonbiologic DMARD: OR 0.61, 95% CI 0.48-0.76; anti-TNF: OR 0.85, 95% CI 0.75-0.97). CONCLUSION: Earlier treatment was associated with a greater likelihood of remission.
OBJECTIVE: To examine whether disease duration is an independent predictor of achieving remission in rheumatoid arthritis (RA) patients initiating therapy. METHODS:RApatients in the Consortium of Rheumatology Researchers of North America registry newly prescribed a nonbiologic disease-modifying antirheumatic drug (DMARD) or anti--tumor necrosis factor (anti-TNF) with at least one followup visit were identified. Achievement of remission was defined using the Clinical Disease Activity Index (CDAI; score ≤2.8) and 28-joint Disease Activity Score (DAS28; score <2.6) at any followup visit within one year; sustained remission was defined as remission during any two successive visits. Likelihood of remission was examined through logistic regression based on 5-year increments of disease duration, adjusting for baseline covariates. RESULTS: Among the 1,646 nonbiologic DMARD initiators, CDAI remission occurred in 21.3% of those with ≤5 years of disease duration, 19.6% with 6-10 years, and 13.5% with ≥11 years (P < 0.001); sustained remission occurred in 10.2%, 8.8%, and 2.5%, respectively (P < 0.001). Results were similar among the 3,179 anti-TNF initiators (CDAI remission in 22.3%, 17.7%, and 12.8%, respectively [P < 0.001]; CDAI sustained remission in 9.7%, 9.5%, and 4.2%, respectively [P < 0.001]). DAS28 results were similar in both groups. In adjusted analyses, an increase of disease duration by 5 years was associated with a reduced likelihood of CDAI remission in nonbiologic DMARD (odds ratio [OR] 0.91, 95% confidence interval [95% CI] 0.83-0.99) and anti-TNF initiators (OR 0.88, 95% CI 0.83-0.94). A similar result was seen for sustained remission using the CDAI (nonbiologic DMARD: OR 0.61, 95% CI 0.48-0.76; anti-TNF: OR 0.85, 95% CI 0.75-0.97). CONCLUSION: Earlier treatment was associated with a greater likelihood of remission.
Authors: J A Karlsson; L E Kristensen; M C Kapetanovic; A Gülfe; T Saxne; P Geborek Journal: Rheumatology (Oxford) Date: 2008-02-27 Impact factor: 7.580
Authors: Timo Möttönen; Pekka Hannonen; Markku Korpela; Martti Nissilä; Hannu Kautiainen; Jorma Ilonen; Leena Laasonen; Oili Kaipiainen-Seppänen; Per Franzen; Tapani Helve; Juhani Koski; Marianne Gripenberg-Gahmberg; Riitta Myllykangas-Luosujärvi; Marjatta Leirisalo-Repo Journal: Arthritis Rheum Date: 2002-04
Authors: Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green Journal: Arthritis Rheum Date: 2006-01
Authors: L Gossec; M Dougados; P Goupille; A Cantagrel; J Sibilia; O Meyer; J Sany; J-P Daurès; B Combe Journal: Ann Rheum Dis Date: 2004-06 Impact factor: 19.103
Authors: Esmeralda T H Molenaar; Alexandre E Voskuyl; Huib J Dinant; P Dick Bezemer; Maarten Boers; Ben A C Dijkmans Journal: Arthritis Rheum Date: 2004-01
Authors: Paul Emery; Ferdinand C Breedveld; Stephen Hall; Patrick Durez; David J Chang; Deborah Robertson; Amitabh Singh; Ronald D Pedersen; Andrew S Koenig; Bruce Freundlich Journal: Lancet Date: 2008-07-16 Impact factor: 79.321
Authors: Scott W Baumgartner; Roy M Fleischmann; Larry W Moreland; Michael H Schiff; Joseph Markenson; James B Whitmore Journal: J Rheumatol Date: 2004-08 Impact factor: 4.666
Authors: Damini Jawaheer; Susan Messing; George Reed; Veena K Ranganath; Joel M Kremer; James S Louie; Dinesh Khanna; Jeffrey D Greenberg; Daniel E Furst Journal: Arthritis Care Res (Hoboken) Date: 2012-12 Impact factor: 4.794
Authors: Bernard Combe; Alan Kivitz; Yoshiya Tanaka; Désirée van der Heijde; J Abraham Simon; Herbert S B Baraf; Uma Kumar; Franziska Matzkies; Beatrix Bartok; Lei Ye; Ying Guo; Chantal Tasset; John S Sundy; Angelika Jahreis; Mark C Genovese; Neelufar Mozaffarian; Robert B M Landewé; Sang-Cheol Bae; Edward C Keystone; Peter Nash Journal: Ann Rheum Dis Date: 2021-01-27 Impact factor: 19.103
Authors: Paul Emery; Gerd R Burmester; Vivian P Bykerk; Bernard G Combe; Daniel E Furst; Emilie Barré; Chetan S Karyekar; Dennis A Wong; Tom W J Huizinga Journal: Ann Rheum Dis Date: 2014-11-03 Impact factor: 19.103
Authors: David J Kreps; Florencia Halperin; Sonali P Desai; Zhi Z Zhang; Elena Losina; Amber T Olson; Elizabeth W Karlson; Bonnie L Bermas; Jeffrey A Sparks Journal: Int J Clin Rheumtol Date: 2018
Authors: Frank Behrens; Paul P Tak; Mikkel Østergaard; Rumen Stoilov; Piotr Wiland; Thomas W Huizinga; Vadym Y Berenfus; Stoyanka Vladeva; Juergen Rech; Andrea Rubbert-Roth; Mariusz Korkosz; Dmitriy Rekalov; Igor A Zupanets; Bo J Ejbjerg; Jens Geiseler; Julia Fresenius; Roman P Korolkiewicz; Arndt J Schottelius; Harald Burkhardt Journal: Ann Rheum Dis Date: 2014-02-17 Impact factor: 19.103